SEC Company Response from TuHURA Biosciences, (HURA) — May 23, 2019

TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: May 23, 2019 · CIK: 0001498382 · Accession: 0001213900-19-009522

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-230929

Date

May 23, 2019

Author

Saiid Zarrabian

Form

CORRESP

Company

TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)

Letter

DelMar Pharmaceuticals, Inc.

Suite 720-999 West Broadway

Vancouver, British Columbia, Canada V5Z 1K5

May 23, 2019

VIA EDGAR SUBMISSION

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, NE

Washington, D.C. 20549

Re: REQUEST FOR ACCELERATION OF EFFECTIVENESS

DelMar Pharmaceuticals, Inc.

Registration Statement on Form S-1, as amended

File No. 333-230929

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced registration statement to Tuesday, May 28, 2019, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

Once the registration statement has been declared effective, please orally confirm that event with Alexander Dinur of Lowenstein Sandler LLP at (973) 422-6732.

Very truly yours,
DelMar Pharmaceuticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

DelMar
Pharmaceuticals, Inc.

Suite
720-999 West Broadway

Vancouver,
British Columbia, Canada V5Z 1K5

May
23, 2019

VIA
EDGAR SUBMISSION

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, NE

Washington,
D.C. 20549

    Re:
    REQUEST
    FOR ACCELERATION OF EFFECTIVENESS

    DelMar Pharmaceuticals,
    Inc.

    Registration
    Statement on Form S-1, as amended

    File No. 333-230929

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the above-referenced
registration statement to Tuesday, May 28, 2019, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

Once
the registration statement has been declared effective, please orally confirm that event with Alexander Dinur of Lowenstein Sandler
LLP at (973) 422-6732.

    Very truly yours,

    DelMar Pharmaceuticals, Inc.

    By:
    /s/
    Saiid Zarrabian

    Name:
    Saiid Zarrabian

    Title:
    Chief Executive Officer

SecProbe.io